Special Products

Special Products Limited is a UK-based specialty pharmaceutical company focused on the development, licensing, and marketing of niche medicines for specialized patient populations. The company historically specialized in 'specials' (unlicensed medicines) before transitioning many of its core products to licensed status, particularly in the fields of pediatric epilepsy and palliative care. Its most notable development was the oromucosal midazolam product, Epistatus, used for the treatment of prolonged acute convulsive seizures. In 2020, the company was acquired by the French pharmaceutical group Ethypharm, integrating its portfolio into Ethypharm's UK operations to bolster their presence in the central nervous system and critical care markets.